Navigation Links
AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin,Cells Have the Ability to Recognize, Transport and Utilize,L-ergothioneine (EGT) As A Protector Against Oxidative Damage

by western, blot analysis.

The study also examined whether this new patented form of EGT further exhibited properties of a super-antioxidant, and therefore EGT's beneficial role in the treatment of photodamaged skin. Study results show that NHDF treated with EGT had significant lower levels of hydroxyl radicals over a one-hour period than those treated with idebenone, a synthesized form of CoQ10 which has also been thought to exhibit exceptional antioxidant properties.

AGI Dermatics is the developer of Remergent(R), a doctor-dispensed skincare line based on the science of DNA repair. AGI manufactures Remergent(R) Clarifying Concentrate, a formula designed to treat hyperpigmentation, which contains EGT as a key ingredient. EGT has also been shown to be clinically effective in enhancing skin brightness.

About AGI Dermatics

AGI Dermatics is the bio-pharmaceutical laboratory that has led the research of DNA repair of the skin for more than 20 years. Founded by Daniel B. Yarosh, PhD, AGI Dermatics specializes in skin photobiology, dedicating research and development to DNA repair, solar impact on the immune system, and cell-signaling in skin. The company's application of groundbreaking active ingredients and meticulously engineered liposome delivery systems is validated in controlled clinical studies and published in dozens of peer-reviewed scientific and medical journals. www.agiderm.com

CONTACT: Courtney McGeever for AGI Dermatics, +1-212-317-1462

Web site: http://www.agiderm.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2

Related medicine technology :

1. AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1 Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV Irradiated Skin Cells
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:5/12/2008)...Patients in Cohort 3 Demonstrated Improvement in T...rapeutic Potential of HspE7, SAN DIEGO, May 12 /P...Corporation (TSX: NVN) today announced positive im...ing Phase 1 clinical trial of its lead product,can...helial neoplasia, or,CIN, a precursor to cervical ...
(Date:5/9/2008)...A, Fla., May 9 /PRNewswire-USNewswire/ -- Osteoart...ondition that affects almost 50,million people in ...f,cartilage in bone joints. The novel investigatio... oral analgesic, provided significant relief,for p... treated with,placebo, and with fewer gastrointest...
(Date:5/9/2008)...TTLE, May 9 /PRNewswire-USNewswire/ -- The risk of...n prostatic hyperplasia (BPH), can be,reduced by c...ntaining a,normal weight and eating a healthy diet...cer Prevention Program at Fred Hutchinson Cancer R...ies that suggest men need not,feel helpless agains...
(Date:5/9/2008)...th International Phase III Study Shows Positive Re...ata -, NUTLEY, N.J., May 9 /- Roche ...ar Phase III study showing that ACTEMRA(TM),(tocil...tructural damage to,joints in patients with rheuma...veness of an RA treatment. The study also demonstr...
Breaking Medicine Technology:Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 2Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 3Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15) 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5Memory in artificial atoms 4445 1Memory in artificial atoms 4445 2Faster Test Detects Fake Tamiflu Drugs 16192 1Faster Test Detects Fake Tamiflu Drugs 16192 2Chehalis Tribes Announce Benefit to Help Returning Combat Veterans 16187 1Chehalis Tribes Announce Benefit to Help Returning Combat Veterans 16187 2Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 16183 1Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 16183 2Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph 16183 3
... Vaginal Supplement Studied in Largest-Ever IVF Tr...PRNewswire/ -- Results of,four studies evaluating ...ogesterone vaginal insert in development for lutea...t for implantation and,the early stages of pregnan...re presented at the 55th Annual Meeting of the,Pac...
... N.J., April 18, 2007 /PRNewswire-FirstCall/ --,ON...rug candidate,may have potential as a chemopreven...ma researcher Michele Carbone M.D., Ph.D.,at this...AACR),Annual Meeting. , In a series of poster pres...ldwide problem of asbestos exposure and its link t...
Other Medicine Technology:Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 2Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 3Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 4Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting 5Onconase has Potential as Chemopreventive Agent in Mesothelioma,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting 2Onconase has Potential as Chemopreventive Agent in Mesothelioma,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting 3Onconase has Potential as Chemopreventive Agent in Mesothelioma,Reports World-Renowned Mesothelioma Researcher at AACR Annual,Meeting 4
(Date:5/13/2008)... HARBIN, China, May 13 /Xinhua-PRNewswire-FirstCa...oard: CSKI), a manufacturer, marketer and,distribu...oducts in China,today announced that it will cond... May 15, 2008 to discuss its first quarter 2008 fi...man, CEO and Director of China Sky One,Medical, In...
(Date:5/13/2008)...ildbearing had no such benefit if baby was bottle-...13 (HealthDay News) -- Women who breast feed for m...arthritis (RA) by half, according to a new Swedish...g children but not breast-feeding offered women no...contraceptives also failed to reduce the risk of R...
(Date:5/13/2008)...NEW YORK (May 13, 2008) -- Promising results from ...ell Medical Center physician-scientists show that ... the progression of Batten disease, or Late Infant..., genetic, degenerative neurological disorder that... to 12. , The clinical trial found that the pro...
(Date:5/13/2008)... SALT LAKE CITY, May 13 /PRNewswire/ -- Paramed S...ent of their marine-grade Mobility Offers,Versatil...chair to oil and,gas platform operators in the Gul...platforms will enable the safe and timely evacuati...atform., Paramed developed the dual-track MOV in ...
Breaking Medicine News(10 mins):Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Breast-feeding Might Shield Women From Rheumatoid Arthritis 2Health News:NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease 2
...ltinational team of researchers based in the UK ha...s biological barriers, opening up the potential fo...rchers from the School of Pharmacy, University of ...otubes by adding a range of different functional g...
...U.S. Food and Drug Administration (FDA) today clea... device that can help save the arms and legs of so...ndividuals in other trauma settings and emergency ... Limb Salvage Shunt (TLSS), made by Vascutek Ltd. ...
...a's drug major Ranbaxy Laboratories has received t...pproval to manufacture// and market its formulatio...in adults. Ranbaxy Pharmaceuticals Inc. (RPI), a ...oratories Limited (RLL), announced Friday that FDA...
...he recent years, scientists discovered a family of...xtend life in organisms// as diverse as yeast, wor...t The Wistar Institute points to another strategy ...ir anti-aging powers. They may also be able to con...
Other Medicine News:Health News:Carbon Nanoneedles For Drug Delivery 2Health News:Carbon Nanoneedles For Drug Delivery 3Health News:Carbon Nanoneedles For Drug Delivery 4Health News:FDA Clears Critical Limb-Saving Vascular Device 2Health News:Anti-Aging Powers of Enzyme Sirtuins 2
VG2 PLIF Allograft is comprised of two cortical planks of bone surrounding a cancellous center. The cortical planks provide strength for anterior column support. The cancellous bone provides a lattic
Williams Micro Discectomy Instruments are designed to be used in the microsurgical treatment of herniated disks.
Meyerding Laminectomy Retractors, self-retaining.
Karlin Crank Frame Spinal Retractor Set is designed for posterior lumbar and thoracic spine surgery. Arm design allows the blades be pre-positioned in the wound prior to attachment.
Medicine Products: